Trial Profile
A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2022
Price :
$35
*
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Partial epilepsies; Seizures
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 21 Feb 2018 Results published in the GW Pharmaceuticals Media Release
- 05 Feb 2018 According to a GW Pharmaceuticals media release, data from this trial is expected in Q1 2018.
- 18 Dec 2017 Status changed from active, no longer recruiting to completed.